Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ultragreen AiFRA:U5T -4.59%31 Debt-to-EBITDA is 0.05 as of Jun. 2026, which is 94% below its 10-year median of 0.88. GuruFocus rates FRA:U5T with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 478 Healthcare Providers & Services companies, Ultragreen Ai ranks better than 95.82% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ultragreen Ai's Debt-to-EBITDA or its related term are showing as below:
FRA:U5T'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.04 Med: 0.88 Max: 2.09
Current: 0.05
During the past 4 years, the highest Debt-to-EBITDA Ratio of Ultragreen Ai was 2.09. The lowest was 0.04. And the median was 0.88.
FRA:U5T's Debt-to-EBITDA is ranked better than 95.82% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.19
vs FRA:U5T: 0.05
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ultragreen Ai Debt-to-EBITDA Related Terms
Ultragreen Ai Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ultragreen Ai's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:U5T vs VEEV, BTSG, HQY: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, Ultragreen Ai's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ultragreen Ai Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ultragreen Ai's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ultragreen Ai's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Ultragreen Ai (FRA:U5T) has a Debt-to-EBITDA of 0.05 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ultragreen Ai. This is 94% below median its historical median of 0.88. Over the past decade, Ultragreen Ai's Debt-to-EBITDA has ranged from 0.04 to 2.09. According to the industry distribution chart, Ultragreen Ai ranks #20 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 4.2%.
Is Ultragreen Ai's Debt-to-EBITDA too high?
Ultragreen Ai's current Debt-to-EBITDA of 0.05 is 94% below median its 10-year median of 0.88. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 2.09. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. Ultragreen Ai's value of 0.05 is 97.7% below this industry median. Based on the distribution chart, Ultragreen Ai ranks #20 out of 478 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Ultragreen Ai has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Ultragreen Ai's Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Ultragreen Ai ranks #20 out of 478 companies for Debt-to-EBITDA. This places Ultragreen Ai in the top 4% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.19. Ultragreen Ai's value of 0.05 is 97.7% below this benchmark. Historically, Ultragreen Ai's own Debt-to-EBITDA has ranged from 0.04 to 2.09 over the past decade. While the company's 10-year median is 0.88 vs. the industry median of 2.19, Ultragreen Ai has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ultragreen Ai's current Debt-to-EBITDA of 0.05 is 97.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ultragreen Ai. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ultragreen Ai's current Debt-to-EBITDA is 0.05, which is 94% below median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragreen Ai stock overvalued right now?
Ultragreen Ai (FRA:U5T) has a current Debt-to-EBITDA of 0.05. The current Debt-to-EBITDA is 0.05, which is 94% below median its 10-year median of 0.88 and 97.7% below the Healthcare Providers & Services industry median of 2.19. Ultragreen Ai's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ultragreen Ai (FRA:U5T), the current Debt-to-EBITDA is 0.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ultragreen Ai Ltd is engaged in the sales of Indocyanine Green (ICG) pharmaceutical products and cardiology Picture Archiving and Communication System (PACS) software and associated products and services. It provides a fluorescence imaging ecosystem designed to support surgeons with real-time perfusion data and visualization capabilities. The company is organised into business units based on its products and services and operates in (a) the Diagnostic Green (DxG) - Americas segment; (b) the DxG - Rest of the World segment; and (c) the UltraLinQ segment. The company generates the maximum of its revenue from the the DxG - Rest of the World segment, which focuses on the sales of ICG vials and related pharmaceutical products.
31GF Score
Get the complete analysis for FRA:U5T
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:U5T has been successfully added to your 
